A-Alpha Bio Announces Collaboration With Gilead to Advance Next-Generation HIV Therapeutic Options

We’re excited to share the news of our new collaboration with Gilead Sciences, the world’s leading developer of HIV drugs, to help discover advanced long-acting biologics for HIV treatment. By leveraging our expertise in synthetic biology and machine learning, the partnership aims to develop therapeutics that neutralize HIV, even in its various mutable forms. 

Our work together will begin by applying the AlphaSeq platform to characterize binding affinities between therapeutic candidates and HIV antigen variants, generating vast amounts of data. This data will feed into AlphaBind, our machine-learning platform, to predict proteins with enhanced binding breadth and resistance to viral escape. Our dual-platform approach uniquely positions us to discover and optimize biologics with challenging binding requirements, driving the development of highly cross-reactive biologics.

As we work with Gilead, we look forward to contributing to the critical fight against HIV, a disease that continues to pose a significant global health concern. By harnessing the potential of our technology and our collaboration with Gilead, we are taking a step closer to a future where HIV can be effectively managed.

You can read coverage in Timmerman Report here.